Vivasc Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Vivasc Therapeutics's estimated annual revenue is currently $201k per year.
- Vivasc Therapeutics's estimated revenue per employee is $100,500
Employee Data
- Vivasc Therapeutics has 2 Employees.
- Vivasc Therapeutics grew their employee count by 0% last year.
Vivasc Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | EVP Operations | Reveal Email/Phone |
Vivasc Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $46.6M | 232 | 8% | N/A | N/A |
#2 | $84.2M | 419 | 3% | N/A | N/A |
#3 | $14.1M | 70 | 0% | N/A | N/A |
#4 | $1224.3M | 6091 | -9% | N/A | N/A |
#5 | $43.2M | 215 | -4% | N/A | N/A |
#6 | $12.3M | 61 | -6% | N/A | N/A |
#7 | $19.9M | 99 | 41% | N/A | N/A |
#8 | $16.5M | 82 | -5% | N/A | N/A |
#9 | $97.7M | 486 | 30% | N/A | N/A |
#10 | $12.5M | 62 | -16% | N/A | N/A |
What Is Vivasc Therapeutics?
Vivasc Therapeutics is an early stage, pre-clinical cardiac drug development company. We are utilizing the proprietary Cardiac Targeting Peptide (CTP) platform technology to deliver various cargo exclusively to cardiomyocytes in a non-invasive manner. We are actively seeking: Joint development partners for our lead compound, CTP-amio, for the treatment of arrhythmias (atrial fibrillation and ventricular tachycardia) Partners to use CTP as a platform vector to deliver other therapeutic cargo (oligonucleotides, peptides, proteins, drugs, nanoparticles, stem cell therapies, etc.) exclusively to cardiomyocytes
keywords:N/AN/A
Total Funding
2
Number of Employees
$201k
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.1M | 2 | 0% | N/A |
#2 | $0.3M | 2 | 100% | N/A |
#3 | $7.5M | 2 | -33% | N/A |
#4 | $0.1M | 2 | -50% | N/A |
#5 | $0.1M | 2 | 100% | N/A |